Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER):

Français
Author : 
Coudert, B ; Pierga, JY ; Mouret-Reynier, MA ; Kerrou, K ; Ferrero, JM ; Petit, T & al
Newspaper edition : 
Lancet Oncol. - Année 2014 - Volume 15 - Page 1493-502 - PMID 25456368